Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
The Korean Endocrine Society (KES) published clinical practice guidelines for the treatment of acromegaly in 2011. Since then, the number of acromegaly cases, publications on studies addressing medical treatment of acromegaly, and demands for improvements in insurance coverage have been dramatically...
Gespeichert in:
Veröffentlicht in: | Endocrinology and metabolism (Seoul) 2019-03, Vol.34 (1), p.53 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | kor |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The Korean Endocrine Society (KES) published clinical practice guidelines for the treatment of acromegaly in 2011. Since then, the number of acromegaly cases, publications on studies addressing medical treatment of acromegaly, and demands for improvements in insurance coverage have been dramatically increasing. In 2017, the KES Committee of Health Insurance decided to publish a posi-tion statement regarding the use of somatostatin analogues in acromegaly. Accordingly, consensus opinions for the position state-ment were collected after intensive review of the relevant literature and discussions among experts affiliated with the KES, and the Korean Neuroendocrine Study Group. This position statement includes the characteristics, indications, dose, interval (including ex-tended dose interval in case of lanreotide autogel), switching and preoperative use of somatostatin analogues in medical treatment of acromegaly. The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrep-ancies among the expert opinions were found, the experts voted to determine the recommended approach. |
---|---|
ISSN: | 2093-596X |